Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment Outcomes Post-Surgery for Moyamoya Disease

J Neurol; ePub 2018 Sep 8; Kahn, Kaur, Stein, et al

Although readmission after revascularization surgery (RS) for moyamoya disease (MMD) is not uncommon, cerebral hemorrhagic events during the 90-day postoperative period are rare, according to a recent analysis of nationally representative US data. In the Nationwide Readmissions Database, index admissions for MMD and readmissions for ischemic stroke (IS), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) were identified. Researchers summarized demographics and comorbidities, and calculated 30-, 60-, and 90-day readmission rates per 100,000 index admissions. They found:

  • Among 201 index admissions for RS for MMD, mean age (SD) was 41.7 (12.6) years; 75% were female; 24% had diabetes; 53% had hypertension; 40% had hypercholesterolemia; 3% had ICH; 16% had IS; and 1% had SAH.
  • RS was performed at large hospitals in 83%, urban hospitals in 85%, and teaching hospitals in 97%.
  • 80% were discharged home; 34% had a readmission during follow-up.
  • Leading reasons for readmission up to 90 days included MMD (62%), postoperative infection (10%), sickle cell crisis (4%), ischemic stroke (4%), epilepsy (2%), subdural hemorrhage (2%) and headache (2%).

Citation:

Kahn A, Kaur G, Stein L, Tuhrim S, Dhammon MS. Treatment course and outcomes after revascularization surgery for moyamoya disease in adults. [Published online ahead of print September 8, 2018]. J Neurol. doi: 10.1007/s00415-018-9044-z.

This Week's Must Reads

Vegetable/Fruit Intake Benefits Cognitive Function, Neurology; ePub 2018 Nov 21; Yuan, Fondell, et al

Alzheimer Dementia and Age-Related Neuropathologies, Ann Neurol; ePub 2018 Nov 12; Boyle, Yu, et al

Kidney Function and Post-Stroke Mortality Examined, Stroke; ePub 2018 Nov 9; El Husseini, Fonarow, et al

Meditation May Help to Alleviate US Stroke Burden, J Stroke Cerebrovasc Dis; ePub 2018 Nov 24; Ambavane, et al

Must Reads in Rare Diseases

Treatment Outcomes Post-Surgery for Moyamoya Disease, J Neurol; ePub 2018 Sep 8; Kahn, Kaur, Stein, et al

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16

Cerebral Cavernous Malformation in the Elderly , JAMA Neurol; ePub 2017 May 8; Flemming, et al